Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oprozomib with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma
NL-OMON46679Phase 1Withdrawn
- Sponsor
- Amgen
- Start
- Jan 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of oprozomib, pomalidomide and dexamethasone in multiple myeloma (MM) (2 arms), sponsored by Amgen. Primary endpoints: Maximum tolerated dose for each oprozomib formulation and Safety and tolerability. Planned start Jan 2018; status: withdrawn.
02
Drugs
oprozomibpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON46679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46679.